Meridian Bioscience Stock Hits New 52-Week Low (VIVO)

NEW YORK ( TheStreet) -- Meridian Bioscience (Nasdaq: VIVO) hit a new 52-week low Friday as it is currently trading at $16.81, below its previous 52-week low of $16.89 with 202,860 shares traded as of 3:17 p.m. ET. Average volume has been 297,300 shares over the past 30 days.

Meridian Bioscience has a market cap of $749.2 million and is part of the health care sector and drugs industry. Shares are down 24.4% year to date as of the close of trading on Thursday.

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. The company has a P/E ratio of 29.4, above the average drugs industry P/E ratio of 29 and above the S&P 500 P/E ratio of 17.7.
  • Practice your VIVO trading strategies and win cash in our stock game.

TheStreet Ratings rates Meridian Bioscience as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and increase in net income. However, as a counter to these strengths, we also find weaknesses including premium valuation and relatively poor performance when compared with the S&P 500 during the past year. You can view the full Meridian Bioscience Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing